Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep543 | Hot topics (including COVID-19) | ECE2020

Are women with osteoporosis treated with denosumab at risk of severe COVID-19?

Maria Formenti Anna , Pedone Erika , Di Filippo Luigi , Massimo Ulivieri Fabio , Giustina Andrea

Coronavirus disease 2019 (COVID-19), is a primarily respiratory infection which can lead to severe syndrome needing hospitalization and assisted ventilation with high lethality. In a recent meta-analysis of 33 RCTs increased risk of severe infections on treatment with Denosumab, widely used for treatment of osteoporosis, was found specifically for ear, nose, and throat. In fact, by inhibiting the receptor activator of nuclear factor κ-Β ligand, denosumab acts as an i...

ea0070aep592 | Pituitary and Neuroendocrinology | ECE2020

Morphometric vertebral fractures are highly prevalent in patients with non-functioning pituitary adenoma and related to older age and hypopituitarism

Frara Stefano , Di Filippo Luigi , Doga Mauro , Maria Formenti Anna , Losa Marco , Resmini Eugenia , Tecilazich Francesco , Mortini Pietro , Giustina Andrea

Introduction: Recent studies showed that morphometric vertebral fractures (VF) are an early and frequent complication in patients (pts) withhyperfunctioning pituitary adenomas and hypopituitarism (independently from the etiology). GH excess or severe deficiency play a negative key role on bone health in this clinical setting. Disease control or adequate replacement therapies still remain a cornerstone for the clinician to reduce the burden of osteo-metabolic complications. To ...

ea0070aep608 | Pituitary and Neuroendocrinology | ECE2020

Metabolism of glucose in patients with acromegaly treated with Pegvisomant and/or Pasireotide LAR after resistance to first generation somatostatin receptor ligands

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Maria Formenti Anna , Maya Fleseriu Cara , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Introduction: Acromegaly (Acro) is characterized by insulin sensitivityreduction, glucose intolerance (IGT) and diabetes mellitus (DM2 in 15%–38% of patients). Studies that investigated action of medical therapies for acro on glucose metabolism, didn’t provide conclusive data. Association between blood glucose (BG) levels and serum IGF-I levels in patients with DM2 and acro has been suggested, however,IGF-I levels and hemoglobin A1c (HbA1c) correlation is still con...

ea0041ep886 | Pituitary - Clinical | ECE2016

Radiological vertebral fractures in patients with acromegaly treated with L-thyroxine

Maffezzoni Filippo , Frara Stefano , Maria Formenti Anna , Mezzone Monica , Cerri Luigi , Porcelli Teresa , Doglietto Francesco , Maroldi Roberto , Mazziotti Gherardo , Giustina Andrea

Acromegaly is associated with skeletal fragility and high risk of vertebral fractures (VFs), but the determinants of such a risk are still under investigation and it is not clear whether replacement therapies of coexistent hypopituitarism may influence prevalence and incidence of VFs. In this cross sectional study, fourty acromegaly patients (24 M, 16 F; median age, 57 years; range, 25–72), 20 with active disease, were evaluated for the effects of replacement therapy of c...